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Summary
Background Sensitive diagnostics are needed for effective management and surveillance of schistosomiasis so that 
current transmission interruption goals set by WHO can be achieved. We aimed to screen the Schistosoma haematobium 
secretome to find antibody biomarkers of schistosome infection, validate their diagnostic performance in samples 
from endemic populations, and evaluate their utility as point of care immunochromatographic tests (POC-ICTs) to 
diagnose urogenital schistosomiasis in the field.
Methods We did a biomarker identification study, in which we constructed a proteome array containing 992 validated 
and predicted proteins from S haematobium and screened it with serum and urine antibodies from endemic 
populations in Gabon, Tanzania, and Zimbabwe. Arrayed antigens that were IgG-reactive and a select group of 
antigens from the worm extracellular vesicle proteome, predicted to be diagnostically informative, were then 
evaluated by ELISA using the same samples used to probe arrays, and samples from individuals residing in a low-
endemicity setting (ie, Pemba and Unguja islands, Zanzibar, Tanzania). The two most sensitive and specific antigens 
were incorporated into POC-ICTs to assess their ability to diagnose S haematobium infection from serum in a field-
deployable format.
Findings From array probing, in individuals who were infected, 208 antigens were the targets of significantly elevated 
IgG responses in serum and 45 antigens were the targets of significantly elevated IgG responses in urine. Of the five 
proteins that were validated by ELISA, Sh-TSP-2 (area under the curve [AUC]serum=0⋅98 [95% CI 0⋅95–1⋅00]; 
AUCurine=0⋅96 [0⋅93–0⋅99]), and MS3_01370 (AUCserum=0⋅93 [0⋅89–0⋅97]; AUCurine=0⋅81 [0⋅72–0⋅89]) displayed the 
highest overall diagnostic performance in each biofluid and exceeded that of S haematobium-soluble egg antigen in 
urine (AUC=0⋅79 [0⋅69–0⋅90]). When incorporated into separate POC-ICTs, Sh-TSP-2 showed absolute specificity 
and a sensitivity of 75% and MS3_01370 showed absolute specificity and a sensitivity of 89%.
Interpretation We identified numerous biomarkers of urogenital schistosomiasis that could form the basis of novel 
antibody diagnostics for this disease. Two of these antigens, Sh-TSP-2 and MS3_01370, could be used as sensitive, 
specific, and field-deployable diagnostics to support schistosomiasis control and elimination initiatives, with particular 
focus on post-elimination surveillance.
Funding Australian Trade and Investment Commission and Merck Global Health Institute.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Schistosomiasis, caused by infection with parasitic blood 
flukes of the genus Schistosoma, has a global burden of 
1·86 million disability-adjusted life-years.1 Schistosoma 
haematobium is the most common cause of urogenital 
schistosomiasis in humans, responsible for infection in 
approxi mately half of the estimated 200 million people 
with the disease throughout the world’s tropical and 
subtropical regions.2 Moreover, S haematobium infection 
in women substantially increases the risk of acquiring 
HIV/AIDS,3 and the International Agency for Research 
on Cancer recognises urogenital schisto somiasis as a 
group 1 carcinogen because of its association with 
squamous cell carcinoma of the bladder.4 The focus of 
the schistosomiasis intervention agenda is shifting from 
morbidity control to elimination, and a WHO-mandated 
objective exists to eliminate the disease as a public health 
concern and interrupt transmission in selected areas.5 It 
is therefore imperative that methods to detect infection 
are appropriately sensitive and rapid to diagnose new 
cases, assess effectiveness of elimination measures, and 
be applicable to large-scale surveillance, particularly at 
the post-elimination stage and in children who have not 
yet been exposed.
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Although there is no gold-standard recommended 
technique for detection of schistosomiasis,6 a widely 
used method for diagnosing infection involves 
microscopy-based detection of parasite eggs in urine 
(S haematobium) or faeces (Schistosoma mansoni and 
Schistosoma japonicum), which can have poor sensitivity 
in areas of low transmission,7 limiting its diagnostic 
value in regions of low endemicity. Compared with 
microscopy, microhaematuria detection strips offer an 
alternative for the diagnosis of S haematobium infection; 
however, results need to be interpreted with caution as 
microhaematuria can also result from other medical 
conditions.6 Tests to detect circulating schistosome 
antigen in the blood or urine are typically more sensitive 
than traditional microscopy but are not without 
limitations. For example, an assay to detect circulating 
cathodic antigen in urine is available as a point of 
care test that has excellent capability for diagnosing 
moderate to high level S mansoni infection,6 but reduced 
performance in detecting S haematobium infection.8 
Assays to detect antibodies to crude parasite preparations 
in urine, such as soluble egg antigen, correlate with 
urine egg and serum anodic antigen concentrations;9 
however, they can have low specificity and reproducibility 
due to the antigenic complexity of the extract and 
crossreactivy with other helminthiases. A handful of 
immunodiagnostics based on recombinant antigens 
have been developed for schistosomes, as reviewed 
by Hinz and colleagues.10 However, to our knowledge, 
diagnostic performance has only been assessed using 
serum from individuals who are infected.
The upsurge in availability of so-called omics 
information for the schistosomes over the past decade 
has set the stage for the development of new antigen 
discovery technology platforms, notably proteome 
microarrays, which use a cell-free expression system to 
produce hundreds or thousands of recombinant 
proteins that are printed on nitrocellulose arrays coated 
on glass slides. We and others have previously used 
array and alternate technologies to study the humoral 
response to S mansoni11–13 and S japonicum,14 probing the 
arrays with serum samples from infected hosts to aid in 
genome-wide vaccine antigen and serological marker 
discovery. Our previous efforts focused on proteins 
secreted by and anchored on the surface tegument 
of the parasites; since 2015, helminths (including 
schistosomes) have been shown to secrete extracellular 
vesicles as a method of host–parasite communication, 
and their proteomes are a rich source of vaccine 
and diagnostic candidates, as reviewed by Sotillo and 
colleagues.15 Of particular relevance to this study is the 
integral membrane tetraspanins, which are abundant 
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Research in context
Evidence before this study
We searched PubMed from database inception to Feb 1, 2021, 
for studies on diagnostic biomarkers for urogenital 
schistosomiasis, using the search terms “schistosomiasis” AND 
“haematobium” AND (“antibody” OR “serodiagnosis” OR 
“immunomics” OR “protein microarray” OR “proteome” OR 
“extracellular vesicle”), without language restrictions. We 
identified 309 studies, one of which was directly relevant in 
terms of diagnostic antibody biomarkers against defined 
protein antigens of Schistosoma haematobium, one for 
Schistosoma mansoni and one for Schistosoma japonicum. 
None of these studies took an unbiased approach to screening 
the secretome of S haematobium for antibody biomarkers of 
urogenital schistosomiasis. Infection with schistosomes 
contributes substantially to the global burden of disease and, in 
the early 2010s, the 56th World Health Assembly called on all 
schistosomiasis-endemic countries to strengthen disease 
surveillance and control measures with the aim of eliminating 
the disease as a public health threat and interrupting 
transmission in selected areas by 2025. Although undeniable 
progress towards these goals has been made in some regions, 
nearly a decade since these objectives were defined, 
schistosomiasis still remains highly prevalent. Moreover, it is 
apparent that available diagnostic tools are not sufficiently 
sensitive, specific, or field-deployable to ensure reliable disease 
surveillance, thereby limiting the effectiveness of control, and 
particularly elimination campaigns.
Added value of this study
To respond to the need for novel diagnostics for 
schistosomiasis, we searched for biomarkers of infection 
present in the serum and urine of individuals infected with 
S haematobium, the most common schistosome infecting 
humans and the cause of urogenital schistosomiasis. 
We undertook an integrated high-throughput immunomics-
guided screen of the S haematobium secretome. The diagnostic 
performance of selected biomarkers was validated by ELISA 
using serum and urine from areas of differing schistosomiasis 
transmission dynamics and, in some cases, outperformed that 
of S haematobium-soluble egg antigen, a crude parasite 
extract widely used for immunodiagnosis of the disease. 
Finally, and with the aim of developing a novel field-
deployable diagnostic for schistosomiasis, two of the most 
sensitive and specific antigens were incorporated into pilot 
point of care immunochromatographic tests capable of 
diagnosing S haematobium infection in serum with a 
sensitivity rate of at least 79%.
Implications of all the available evidence
We have identified new immunodiagnostics for 
S haematobium that could be sufficiently sensitive and specific 
in their diagnostic capacity to augment existing 
schistosomiasis surveillance and elimination strategies, 
especially in regions where interruption of transmission 
has been achieved.
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on the extracellular vesicle surface and known to be 
immunogenic in other helminth infections.
In this study, we aimed to use the S haematobium 
surface and soluble and vesicular secreted proteomes16,17 
to create the first S haematobium protein microarray, 
which, containing 992 proteins is the largest created 
for a multicellular pathogen to our knowledge. In an 
integrated approach to identify diagnostic markers for 
urogenital schisto somiasis, we probed the proteome 
array with the serum and urine of individuals from two 
geographically distant S haematobium-endemic regions 
to establish targets of IgG responses, and selected a 
subset of surface antigens from the extracellular vesicle 
proteome. Candidates from both selection methods have 
been validated by ELISA using both diagnostic fluids 
and, in the early phase transition of our research from 
bench to field, we documented results from pilot testing 
of the first point of care immunochromatographic test 
(POC-ICT) based on two of these antigens.
Methods
Study design and cohorts
We did a biomarker identification study. All samples 
used in this study were acquired from previous studies 
and had been stratified on the basis of egg burden as 
established by microscopy analysis of urine samples 
(high, ≥50 eggs per 10 mL urine; or light, 1–49 eggs 
per 10 mL urine). Egg-negative samples were further 
tested for the presence of circulating anodic antigen 
(CAA) using the up-converting phosphor lateral flow 
CAA assay9 and were classified as being egg-negative and 
CAA-positive or egg-negative and CAA-negative. Protein 
arrays were probed with serum and urine samples 
from S haematobium-endemic regions of Gabon and 
Zimbabwe. ELISAs were done with the same cohorts of 
serum samples from Gabon and Zimbabwe and the 
same cohort of urine samples from Zimbabwe only 
(the Gabon urine cohort had been exhausted from array 
probing). Additional ELISA vali dation was done with 
urine samples from an elimination setting: Pemba and 
Unguja islands, Zanzibar, Tanzania. Species specificity 
analysis was done with S japonicum-infected samples 
from the Philippines, and S mansoni-infected samples 
from Ethiopia. ICT evaluation was done with serum 
samples from the Gabon cohort (appendix p 3). A 
schematic of the study design is shown in figure 1 and a 
detailed method is described in the appendix (p 8). All 
samples came from studies with ethical approval. Ethical 
approval details for both the published and unpublished 
studies are shown in the appendix (p 8). Written informed 
consent was required and obtained in the original 
studies.
Procedures
For protein array construction, probing, and analysis, 
proteins present in the adult S haematobium tegument, 
soluble excretory and secretory products and extracellular 
vesicles, and excretory and secretory products from the 
egg stage,16,17 S haematobium orthologues of the S mansoni 
schistosomula tegument proteome,18 and select proteins 
from the S mansoni proteome array12 were chosen for 
printing on the S haematobium array (appendix p 15). 
Array construction was the same as described previously13 
except that open reading frames of arrayed proteins 
were synthesised instead of amplifying every gene from 
parasite complementary DNA using PCR. Parasite 
extracts were included on the array as positive controls.
Serum IgG responses to arrayed antigens were 
established by probing with human serum samples 
(one part to 50 parts) in array blocking buffer and 
10% Escherichia coli lysate) as previously described13 with 
the exception that an anti-human IgG-Qdot conjugate 
(Grace Biolabs, Bend, OR, USA; one part to 100 parts in 
array blocking buffer) was used as the secondary or 
detection antibody. Urine IgG responses were 
established by probing arrays in the same way except 
that human urine samples were first concentrated 15-fold 
and buffer-exchanged into phosphate-buffered saline 
before being diluted one part to five parts in array 
blocking buffer and 10% E coli lysate.
Statistical analysis
For protein array data analysis and bioinformatics, datasets 
generated from probing arrays with serum and urine were 
analysed separately. Significant differences between mean 
antibody responses in the infected versus non-infected 
groups were determined by Student’s t test. Receiver-
operating characteristic (ROC) curves and area under the 
curve (AUC) values were generated for each antibody 
response using the ROCR R package, version 4.0.2, and 
the protein targets of those responses were ranked in order 
of response significance.
A set of antigens producing an antibody signature that 
could most effectively discriminate between individuals 
who were infected and non-infected, using either serum 
or urine as the diagnostic fluid, was identified. Firstly, for 
each dataset, all antigens that were the target of an 
antibody response that was significantly higher in the 
infected than non-infected populations were selected. 
From these, antigen targets of responses with a frequency 
of positivity (reactivity) in less than 30% of the infected 
population and more than 30% of the non-infected 
population were also excluded. Antigens in these 
trimmed datasets were sorted by greatest to least fold 
change in mean signal intensity between the infected 
and non-infected populations and frequency of reactivity 
in the infected population. The most effective antigens in 
each dataset were used to build a support vector machine 
classifier, the performance of which was evaluated by 
Monte Carlo cross-validation.19
For selection of extracellular vesicle-derived tetras-
panins, tetraspanins present in the S haematobium 
extracellular vesicle proteome were sorted by abundance16 
(peptide spectrum counting), and the most abundant 
See Online for appendix
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tetraspanins with homologues of diagnostic efficacy 
reported in the literature (n=3) were selected for further 
assessment.
Eight antigens, selected from the immune signature 
and extracellular vesicle proteomic set (MS3_10385, 
MS3_10186, MS3_06193, MS3_01466, MS3_05950, 
MS3_09198, MS3_01370, and Sh-TSP-2), were expressed 
in E coli as previously described.20 Expression yields 
of MS3_06193, MS3_01466, and MS3_05950 were at 
concentrations too low to warrant further development.
IgG responses to E coli-expressed and purified recom-
binant proteins in each biofluid were measured by 
ELISA. Plates (Greiner, Kremsmunster, Austria) were 
coated with antigen, blocked and probed with serum 
(one part to 50 parts) followed by goat anti-human 
IgG-horseradish peroxidase (Sigma, St Louis, MO, 
USA, one part to 5000 parts), and developed with 
3,3’,5,5’-tetramethyl benzidine. Urine IgG responses to 
each antigen were measured in a similar way except that 
urine samples were diluted one part to ten parts with 
phosphate-buffered saline. Urine IgG responses to 
multiple antigens were done in the same way and plates 
were coated with antigen diluted to 2 μg/mL. Species 
specificity analysis was done as for serum ELISAs. Assays 
were done in triplicate and blank-corrected values were 
plotted using Graphpad Prism, version 7. Reactivity 
cutoffs were determined as the mean plus three 
SDs of the non-endemic negative group. ROC curves 
were generated using Graphpad Prism, version 7, and 
significant differ ences between mean antibody responses 
of each infected group and the non-infected group were 
determined by Student’s t test.
For POC test development, a lateral flow ICT 
was designed (Serve Science, Bangkok, Thailand; 
appendix p 94). The conjugate pad was coated with 
10 optical density (OD) of gold-conjugated mouse 
anti-human IgG, 1·0 mg/mL of either recombinant 
MS3_01370, or Sh-TSP-2 (the antigens with the greatest 
diagnostic capacity as established by ELISA) was sprayed 
at the test line, and 1·0 mg/mL anti-mouse IgG was 
sprayed at the control line. Serum (5 μL, diluted one part 
to ten parts in buffer BS-007) was applied to the sample 
reservoir, three drops of buffer BS-007 was applied to the 
sample reservoir, and the test was read after 15 min. For 
each strip, bands at the test and control lines indicated a 
positive result, a band at the control line only indicated a 
negative result, and the test was invalid if there was no 
band at the control line. Band intensity on positive tests 
was scored on a four-point scale from most (+4) to 
least (+1) intense. A score of 0 was given for a negative 
result. Test results were confirmed by two independent 
and masked examiners (AL and BAT).
Role of the funding source
The funders of the study had no role in data collection, 
data analysis, data interpretation, or writing of the report.
Results
Serum and urine IgG responses to numerous arrayed 
antigens were significantly elevated in the infected 
population (ie, samples from all infected cohorts in 
Gabon and Zimbabwe) when compared with the non-
infected population (ie, the non-infected urine samples 
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protein array (992 antigens)†
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serum samples and urine of individuals with 
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Extracellular vesicle-derived tetraspanins with 
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Figure 1: Schematic overview of the study
We used an integrated approach to identify biomarkers of S haematobium infection. (A) Diagnostic antigens were 
selected using an immunomics approach to select antigens that were targets of significantly elevated infection-
associated IgG responses. (B) Eight antigens were selected for further assessment. (C) Diagnostic performance of 
five recombinant antigens expressed in Escherichia coli was validated by ELISA. (D) The two highest performing 
antigens were each incorporated into a separate POC-ICT and their diagnostic performance further assessed. 
POC-ICT=point of care immunochromatographic test. OD=optical density. *Redundancy between the two antigen 
groups means that the starting number of antigens does not equal the sum total of the two individual datasets. 
†Feature selection for the S haematobium protein array was informed by S haematobium proteomic16,17 and 
Schistosoma mansoni bioinformatic12 datasets. ‡S haematobium extracellular vesicle proteomic data described by 
Mekonnen and colleagues.16
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came from Australia [non-endemic area] and the non-
infected serum samples come from the Netherlands 
[non-endemic area]). 208 antigens were the targets of 
significantly elevated IgG responses in the serum 
of individuals who were infected of 243 total serum 
samples and 45 antigens were the targets of significantly 
elevated IgG responses in the urine of individuals who 
were infected of 117 urine samples (figure 2A, B, 
appendix pp 40, 67). The antigens producing the 20 most 
substantial responses in each dataset are listed 
(appendix p 4) with most of these detected in proteomic 
studies and, of these, at least half in each dataset were 
identified from the extracellular vesicle portion of the 
parasite proteome. Seven (35%) of the 20 antigens were 
shared between the two datasets. A significant correlation 
was seen between serum and urine IgG responses 
(r²=0·651; p<0·0001) from all samples used to probe the 
arrays (serum n=243; urine n=117), supported by a 
significant correlation between the responses from a 
subset of matched (n=17) serum and urine samples 
(r²=0·613; p<0·0001; figure 2C, D). For urine, IgG signal 
intensity was significantly correlated with infection 
intensity (r²=0·234; p=0·014) but there was no correlation 
between infection intensity and serum IgG signal 
intensity (r²=0·087; p=0·18; appendix p 95).
An antibody signature was identified that could most 
effectively discriminate between infected and non-infected 
populations by using either serum or urine as the 
diagnostic fluid (appendix p 6). From this set, it was 
established that a minimum of four antigens were capable 
of producing an antibody signature with a diagnostic 
accuracy (AUC) of 0·98 in either diagnostic sample 
(appendix p 96). Antigens that were the targets of 
this response included IPSE/alpha-1 (MS3_10186), 
serpin (MS3_10385), two tetraspanins (MS3_09198 and 
MS3_01370), and a calcium-binding protein (MS3_05950); 
three (60%) of the five were identified from the 
S haematobium extracellular vesicle proteome.
To validate the diagnostic performance of these 
antigens, five from either the immune signature or extra-
cellular vesicle proteomic set (MS3_10385, MS3_10186, 
MS3_09198, MS3_01370, and Sh-TSP-2) were assessed 
by ELISA (figure 3). Urine IgG responses were further 
assessed using samples from a region of low 
transmission.21
Of the responses to recombinant antigens, the most 
substantially reactive serum antibody in the egg-negative 
and CAA-positive group (the cohort with the lowest 
amount of infection) was to Sh-TSP-2. Of the antibody 
responses to purified recombinant antigens, those serum 
antibodies with the greatest ability to discriminate 
between infected and non-infected populations were 
against MS3_01370 with an AUC of 0·93 (95% CI 
0⋅89–0⋅97); and Sh-TSP-2 with an AUC of 0·98 
(0⋅95–1⋅00; appendix p 7). A frequency of recognition 
pattern analysis among the infected populations revealed 
that, consistent with their high AUC values, MS3_01370 
and Sh-TSP-2 were the two antigens most frequently 
recognised and, especially for Sh-TSP-2, this finding 
was due to greater recognition by individuals with a 
lower infection intensity (figure 3G). Specificity for all 
recombinant antigens was 100% in all cohorts tested 
due to the stringent reactivity cutoff set for all assays. 
Of the three most sensitive and specific tetraspanins 
(Sh-TSP-2, MS3_01370, and MS3_09198), there was 
minimal sequence identity across the exposed large 
extracellular loop (appendix p 99), suggesting that 
immuno logical cross-reactivity is unlikely.
Urine IgG responses to all recombinant antigens in the 
high infection intensity group were significantly reactive. 
Additionally, anti-Sh-TSP-2 responses in both low and 
egg-negative and CAA-positive infection intensity groups 
were also significantly elevated (figure 4). From the five 
tested, the antigens with the greatest diagnostic value in 
urine were Sh-TSP-2 (AUC 0⋅96 [95% CI 0⋅93–0⋅99]) 
and MS3_01370 (AUC 0⋅81 [0⋅72–0⋅89]), which exceeded 
that of S haematobium-soluble egg antigen in urine 
(AUC 0⋅79 [0⋅69–0⋅90]).
AUC values for the responses to all recombinant 
antigens were high (>0·89) in the Zimbabwe cohort and 
modest in the Zanzibar cohort (range 0·57–0·69) for all 
recombinant antigens except Sh-TSP-2 (AUC 0·93 
Figure 2: Serum and urine IgG responses resulting from probing of Schistosoma haematobium protein arrays
Volcano plot showing fold change and significance of IgG responses between infected (S haematobium-endemic) 
and non-infected populations with serum (A) or urine (B). Each individual spot denotes a single arrayed antigen. 
Coloured lines represent different probability thresholds (blue p<0·05; red p<0·01; grey p<0·001). Scatterplot 
showing correlation of serum and urine IgG responses for all samples (serum n=242; urine n=117; C) and matched 
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[95% CI 0·87–0·99]; appendix p 7). For urine, the high 
diagnostic performance of Sh-TSP-2 was reflected in 
the frequency of recognition analysis, which showed 
the superior recognition of this antigen in the low 
infection intensity group (figure 4G). Given the 
differences in frequency of recognition patterns of 
the molecules, we tested combinations of the antigens 
to see if these combinations would elicit higher 
positivity among the infected population. All antigen 
combinations resulted in significant responses from all 
infected cohorts compared with controls (appendix p 97). 
The use of these combinations did not result in an 
increase of AUC or frequency of recognition value in 
the infected population compared with Sh-TSP-2 alone 
(appendix pp 99–100). As with the serum ELISAs, 
specificity for all recombinant antigens in all cohorts 
tested was absolute.
We also sought to establish the recognition of Sh-TSP-2 
and MS3_01370 in serum samples from individuals 
mono-infected with either S mansoni or S japonicum. 
Both antigens were recognised to a substantially lesser 
degree by serum antibodies from S japonicum infections 
and, in the case of Sh-TSP-2, S mansoni infections 
(appendix p 101). Multiple sequence alignments of the 
Figure 3: IgG antibody responses to Escherichia coli-expressed recombinant versions of the most sensitive and specific proteins and Schistosoma haematobium-
soluble egg antigen in serum samples from S haematobium-endemic populations
Anti-MS3_10385 (A), anti-MS3_10186 (B), anti-MS3_09198 (C), anti-MS3_01370 (D), anti-Sh-TSP-2 (E), and anti-S haematobium-soluble egg antigen (F).
Individuals who were egg-positive were characterised (WHO stratification) as either having a high (≥50 eggs per 10 mL urine) or low (1–49 eggs per 10 mL urine) 
intensity infection. Egg– and CAA+ indicates egg-negative individuals who were classified as positive (infected) by the more sensitive CAA detection test. 
Egg– and CAA– indicates egg-negative individuals who were confirmed as antigen-negative by the CAA detection test. Plotted data represent the responses of both 
the Zimbabwe (black symbols) and Gabon (blue symbols) cohorts. Reactivity cutoffs were determined as the mean plus three SDs of the values of the non-endemic 
negative group (red dotted line). Significance was analysed by Student’s t test. Frequency of recognition patterns were established with serum samples from 
individuals who were infected resident in S haematobium-endemic populations (G). Samples are sorted from left to right by decreasing egg burden. To facilitate 
proper comparison, the dataset has been trimmed to exclude any samples not assayed for all five recombinant antigens and S haematobium-soluble egg antigen 
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five most sensitive and specific antigens with their closest 
homologues from human, S japonicum, and S mansoni 
revealed varying degress of identity ranging from 31–99%. 
As expected, identity was generally higher between 
the two African species (S haematobium and S mansoni) 
compared with the Asian species, S japonicum 
(appendix p 102).
Finally, we assessed whether the diagnostic performance 
of Sh-TSP-2 and MS3_01370 could be translated into a 
field-compatible format. ICTs coated with either Sh-TSP-2 
or MS3_01370 detected antibodies at every level of infection 
intensity from the cohort sampled (sensitivity 75% for 
Sh-TSP-2 and 89% for MS3_01370 ), even in individuals 
who were egg-negative by urine filtration and were only 
positive for CAA. Both sets of ICTs had 100% specificity 
(figure 5).
Discussion
Current urogenital schistosomiasis diagnostics are not 
without disadvantages, and the suite of sensitive and 
specific determinants of infection available for this 
purpose is poor. We took an integrated approach to 
identify novel biomarkers of infection with this 
carcinogenic parasite by doing a high-throughput screen 
of the S haematobium predicted immunome with serum 
and urine antibody responses of individuals who are 
infected from geographically distinct regions and 
targeting select tetraspanins from the extracellular vesicle 
Figure 4: IgG antibody responses to Escherichia coli-expressed recombinant versions of the most sensitive and specific proteins and Schistosoma haematobium-
soluble egg antigen in urine from S haematobium-endemic populations
Anti-MS3_10385 (A), anti-MS3_10186 (B), anti-MS3_09198 (C), anti-MS3_01370 (D), anti-Sh-TSP-2 (E), and anti-S haematobium-soluble egg antigen (F). 
See figure 3 legend for details. Plotted data represent the responses of both the Zimbabwe (black symbols) and Zanzibar (red symbols) cohorts. Reactivity cutoffs 
were determined as the mean plus three SDs of the values of the non-endemic negative group (red dotted line). Significance was analysed by Student’s t test. 
Frequency of recognition patterns were established using urine from individuals who were infected resident in S haematobium-endemic populations (G). Samples 
have been sorted from left to right by decreasing egg burden. To facilitate proper comparison, the dataset has been trimmed to exclude any samples not assayed for 
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proteome. Proteins from the parasite secretome were 
selected on the basis of their deployment at the host–
parasite interface, making them likely to be targets of 
an antibody response to infection. The diagnostic 
performance of a subset of antigens was then validated 
by ELISA, probing purified recombinant antigens with 
the same samples used to interrogate arrays as well as 
additional cohorts of urine from a schistosomiasis 
elimination setting. The ELISA for the two most sensitive 
and specific antigens had sensitivities of 97% for 
Sh-TSP-2 and 93% for MS3_01370, and a signature of the 
four most sensitive and specific antigens had a sensitivity 
of 98%. Finally, the cognate antigens of the two highest 
performing validated biomarkers were incorporated into 
pilot POC-ICTs to determine their effectiveness as cheap, 
field-deployable tools for the diagnosis of urogenital 
schistosomiasis.
Responses to many immunoreactive antigens were 
shared between the two fluids, probably because of 
serum leakage into the bladder caused by the transit 
of parasite eggs.22 Historical accounts of urogenital 
schistosomiasis describe the urine of patients who are 
heavily infected as having a deep claret colour23 and the 
presence of haematuria remains a diagnostic parameter 
for detection of urogenital schistosomiasis.6
Antigens targeted by IgG responses that were most 
substantially elevated in the infected population belonged 
to distinct protein families including a serpin that interacts 
with the host complement and coagulation systems;24 a 
saposin domain-containing protein, homologues of which 
are haemolytic and likely to be involved in blood-feeding;25 
the interleukin-4-inducing protein IPSE, which infiltrates 
host cells to exert its immunomodulatory effects;26 and 
tetraspanins, which are major membrane constituents 
of parasite extracellular vesicles and mediate their 
communication with host cells.15 A common feature of 
these proteins is their identification in the extracellular 
vesicle proteome, and there are numerous accounts of 
schistosome proteins with diagnostic potential that have 
been found subsequently to derive from extracellular 
vesicles.27–29 Extracellular vesicles are constitutively secreted 
from schistosomes and their relative abundance and 
stability in biofluids is likely to result in sustained 
stimulation of the host anti-schistosome extracellular 
vesicle immune response, making their constituent 
proteins effective tools for diagnosis.
For each antigen that was validated by ELISA, the AUC 
values for both biofluids were similar to those generated 
by array probing, validating our approach to biomarker 
selection. The highest AUC values and sensitivities 
(combined Gabon and Zimbabwe cohorts) in serum 
samples were generated to MS3_01370 and Sh-TSP-2, 
with the diagnostic performance of Sh-TSP-2 equalling 
S haematobium-soluble egg antigen. AUC values and 
sensitivities in urine for all antigens except Sh-TSP-2 
were significantly lower in the Zanzibar than the 
Zimbabwe cohorts, presumably due to the low infection 
intensity in this elimination setting. Sh-TSP-2 displayed 
equally high diagnostic performance in both cohorts. The 
diagnostic perfor mance of all other recombinant proteins 
was high in the Zanzibar urine cohort, indicating 
their potential diagnostic utility for high-endemicity 
populations.
The diagnostic performance of Sh-TSP-2 in the urine 
samples surveyed exceeded that of S haematobium-soluble 
egg antigen, likely to be due to the non-specific 
anti-S haematobium-soluble egg antigen response in 
non-endemic samples. Non-specific reactivity with 
samples from non-endemic settings or cross-reactivity 
with samples from endemic settings in individuals who 
are poly-parasitised can lead to false-positive results, as 
documented with soluble egg antigen and other extracts.10 
Even defined recombinant antigens of similar diagnostic 
performance to S haematobium-soluble egg antigen, such 
as MS3_01370 in urine, have advantages over the crude 
extract as they can be manufactured to produce a 
standardised diagnostic reagent. Sh-TSP-2 was the most 
Figure 5: Pilot development of a point of care immunochromatographic test for diagnosis of urogenital 
schistosomiasis using serum
(A) Representative tests showing positive results of differing band intensities. (B) Schematic showing positive 
(red boxes) and negative (white boxes) results for MS3_01370 or Sh-TSP-2 immunochromatographic test using 
ELISA-validated serum samples from the Gabon cohort (high, n=10; low, n=22; egg– and CAA+, n=4; egg– and CAA–, 
n=14; non-endemic, n=10). Strips were coated with either MS3_01370 or Sh-TSP-2 at the test line to facilitate 
capture and detection of anti-MS3_01370 or anti-Sh-TSP-2 IgG in serum added to the sample reservoir. Appearance 
of a band at the test and control lines was considered a positive result and a band at the control line only was 
considered a negative result. Test bands were given a score from least (+1) to most (+4) intense and a score of 0 was 
given to a negative result. Two independent readers had to agree on a test result. Every test performed was valid, as 
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reactive of all the antigens by ELISA with samples from 
endemic settings that were both egg-negative and 
CAA-negative, likely to indicate infections in the past 
6–12 months or active but very low intensity infections. 
Although this finding might indicate slow antibody decay 
rates post-treatment and make it harder to establish true 
infection status, we envisage an ultimate POC-ICT test 
that contains multiple antigens, including those with an 
accelerated antibody decay rate such as MS3_01370. 
Empirical testing before and after praziquantel therapy in 
a controlled environment is warranted as these tests evolve 
and undergo validation.
To test the diagnostic performance of MS3_01370 and 
Sh-TSP-2 in a rapid field-deployable format, POC-ICTs 
were developed for each molecule. Serum was chosen as 
the diagnostic sample as we reasoned that the increased 
amount of target antibody in this biofluid would 
maximise the success of a pilot test, which could then be 
optimised for use with urine. Both tests could detect 
infection at all levels of intensity, with the MS3_01370 
ICT being diagnostically superior. Nevertheless, we 
believe that both antigens could be further developed 
into a POC test, and incorporating both antigens into a 
single ICT or similar platform could increase sensitivity 
by capturing a wider anti-schistosome antibody repertoire 
while still retaining epitope accessibility of both antigens.
In the POC-ICTs, there was antibody reactivity to some of 
the samples that were both egg-negative and CAA-negative, 
a result also seen by ELISA. Given that antibodies can 
persist in the host after the parasite has been eliminated, we 
posit that the antibody response seen in these individuals is 
likely to be due to infection in the past 3–12 months. In the 
absence of corroborating testing, a potential limitation of 
using antibodies to diagnose infection can be the inability to 
distinguish between past and current infection; however, 
the utility of antibody-based diagnosis, particularly in 
monitoring of trans mission in areas where elimination has 
been achieved and praziquantel treatment effect monitoring 
is taking place,30 should not be underestimated. Deter-
mination of antibody decay rates post-infection could 
augment diagnostic value in some applications and the 
monitoring of antibody titres to the antigens in this study in 
response to praziquantel treatment will be the subject of 
future investigation.
Given the extensive geographical overlap between 
S mansoni and S haematobium, a species-specific 
diagnostic would be sought after. Although the handful 
of recombinant antigens to diagnose S haematobium 
infection described so far have shown a favourable 
absence of cross-reactivity with non-schistosome 
infections, none of these have displayed species-specific 
reactivity.10 Of the antigens tested, Sh-TSP-2 was 
least cross-reactive with S mansoni infections. Sh-TSP-2 
probably contains multiple B-cell epitopes, and identi-
fication of species-specific epitopes will advance the 
development of a truly species-specific diagnostic 
antigen, should it prove desirable. That said, many areas 
are co-endemic for S mansoni and S haematobium, and 
treatment and elimination strategies are likely to be the 
same for both species, so the development of pan-African 
schistosomiasis diagnostics is of merit.
In summary, we used an integrated immunomics 
approach to identify numerous novel antibody biomarkers 
for the diagnosis of urogenital schistosomiasis in serum 
and urine samples from individuals who were infected. 
Arrayed antigens that were the target of some of the 
most diagnostically precise IgG responses, as well as 
tetraspanins abundantly represented in the extracellular 
vesicle proteome, were validated by ELISA using both 
biofluids. Two of the most promising antigens, Sh-TSP-2 
and MS3_01370, were each incorporated into a field-
deployable POC-ICT to further validate their diagnostic 
performance using serum. Future studies will address 
the performace of pilot POC-ICTs using urine. This study 
represents a truly bench-to-field approach to advance the 
development of urogenital schistosomiasis diagnostics 
and, to our knowledge, is the first report documenting the 
use of recombinant antigens for ICT-based detection of 
any schistosome infection.
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